K4 Elite
K4 Elite
A 37-residue synthetic analog of human amylin (IAPP) carrying three proline substitutions, studied in models of gastric motility signaling, glucagon regulation, and peptide aggregation biophysics.
Pramlintide is a synthetic 37-amino-acid analog of human amylin (islet amyloid polypeptide, IAPP), the peptide co-secreted with insulin from pancreatic beta cells. It differs from the human sequence at three positions - Ala25, Ser28 and Ser29 are replaced with proline residues taken from the rat amylin sequence - and it retains the intramolecular disulfide bridge between residues 2 and 7 [4][5].
Those substitutions were introduced because human amylin readily forms beta-sheet amyloid fibrils in vitro, which complicates handling, formulation and interpretation of experiments. Study reports describe the tri-proline analog as resistant to that beta-conformational transition while retaining activity at amylin receptor complexes [5].
Pramlintide received U.S. FDA approval in 2005 under the trade name Symlin as an adjunct in insulin-treated diabetes, and it remains one of the most extensively characterized amylin-mimetic peptides in the published literature [6].
Amylin signaling is mediated by heterodimeric amylin receptors formed when the calcitonin receptor (CTR) associates with receptor activity-modifying proteins (RAMP1, RAMP2 or RAMP3), producing the AMY1-AMY3 receptor subtypes. Receptor-pharmacology studies describe pramlintide as an agonist at these complexes, signaling through Gas and adenylate cyclase [4].
Downstream research localizes much of the observed activity to the area postrema and adjacent hindbrain nuclei, where investigators report effects on gastric motility signaling and on glucagon secretion from pancreatic alpha cells [1][3].
Young and colleagues used a phenol-red gavage model in rats to compare regulators of gastric emptying. Amylin inhibited gastric emptying with a reported ED50 of approximately 0.42 nmol/kg and was described as roughly 15-fold more potent on a molar basis than GLP-1(7-36)NH2 and about 20-fold more potent than CCK-8 in that model [1].
Vella and colleagues studied the amylin analog in participants with type 1 and type 2 diabetes using scintigraphic measurement of gastric emptying, reporting delayed emptying relative to placebo across the study arms tested [2].
Biophysical work compared monomer conformations of human amylin against the tri-proline analog using molecular-dynamics simulation and conformational analysis, reporting that all three proline substitutions were required to disfavor beta conformations and stabilize helical structure [5].
Review analyses of amylin pharmacology aggregate the receptor-level and physiological literature across preclinical and clinical settings, including glucagon and satiation signaling endpoints [3][4].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.